Abstracts tagged "Disease Activity"

Abstract Number: 2401 • 2018 ACR/ARHP Annual Meeting
The Effects of a Gluten-Free Diet in Juvenile Idiopathic Arthritis – a Pilot Study
Anjali Sura¹, Stacey Fogarty-Brown² and Meredith Riebschleger³, ¹Pediatric Rheumatology, University of Michigan, Ann Arbor, MI, ²Pediatrics, University of Michigan, Ann Arbor, MI, ³Pediatric Rheumatology & Health Services Research, University of Michigan, Ann Arbor, MI
Background/Purpose: The caregivers of children with juvenile idiopathic arthritis (JIA) frequently ask about the utility of dietary restrictions. Some patients and physicians report a good…
Abstract Number: 2600 • 2018 ACR/ARHP Annual Meeting
Clinically Meaningful Improvement in Health-Related Quality of Life and the Association with Disease Activity in Psoriatic Arthritis after Treatment with Guselkumab: Results from a Randomized Placebo-Controlled Phase II Clinical Trial
Laure Gossec¹, Bruce Kirkham², Proton Rahman³, Philip Helliwell⁴, Alice B Gottlieb⁵, Wolf-Henning Boehncke⁶ and Chenglong Han⁷, ¹Rheumatology Department, Hôpital Pitié Salpêtrière, Paris 06 University, Paris, France, ²Guy's & St Thomas' NHS Foundation Trust, London, United Kingdom, ³Rheumatology, St Claires Mercy Hospital, St Johns, NF, Canada, ⁴LIMM, Section of Musculoskeletal Disease, University of Leeds, Leeds, United Kingdom, ⁵Department of Dermatology, New York Medical College, Metropolitan Hospital, New York, NY, ⁶Department of Dermatology and Venereology, Geneva University Hospital, Geneva, Switzerland, ⁷Janssen Global Services, LLC, Malvern, PA
Background/Purpose: To evaluate the effect of guselkumab (GUS) on Health-Related Quality of Life (HRQOL) and correlate changes of HRQOL and disease activity in patients with…
Abstract Number: 2929 • 2018 ACR/ARHP Annual Meeting
Validation of Remission and Lupus Low Disease Activity State As Predictors of Organ Damage in SLE
Michelle Petri¹, Daniel Goldman¹ and Laurence S Magder², ¹Medicine (Rheumatology), Johns Hopkins University School of Medicine, Baltimore, MD, ²Epidemiology and Public health, University of Maryland School of Medicine, Baltimore, MD
Background/Purpose: Outcome measures that combine control of SLE activity and prednisone reduction are clinically relevant. A clinical goal in SLE is to reduce risk of…
Abstract Number: 300 • 2018 ACR/ARHP Annual Meeting
Built-in-Electronic-Medical-Record Disease Activity Calculators and Treat-to-Target in Rheumatoid Arthritis
Arundathi Jayatilleke¹ and Scott Pompa², ¹Department of Rheumatology, Drexel Rheumatology, Philadelphia, PA, ²Rheumatology, Drexel Rheumatology, Philadelphia, PA
Background/Purpose: Rheumatoid arthritis (RA) is a chronic inflammatory arthritis that, if undertreated, can lead to cumulative damage and disability. The goal of treatment is to…
Abstract Number: 567 • 2018 ACR/ARHP Annual Meeting
Non-Surgical Periodontal Therapy Plus Short-Term Antibiotic Treatment May Improve Clinical Disease Activity: A Pilot Study in Difficult to Treat Rheumatoid Arthritis
Burkhard Moeller¹, Philip Bender², Sigrun Eick², Kim Midwood³, Jan Potempa⁴, Stephan Reichenbach⁵, Anja Schwenzer³, Peter M. Villiger⁶ and Alicia Wong³, ¹Rheumatology, Immunology and Allergology, Inselspital, University Hospital of Bern, Bern, Switzerland, ²School of Dental Medicine, University of Bern, Bern, Switzerland, ³Kennedy Institute for Rheumatology, Oxford University, Oxford, United Kingdom, ⁴Department of Microbiology, Faculty of Biochemistry, Biophysics and Biotechnology, Jagiellonian University, Krakow, Poland, ⁵Institute of Social and Preventive Medicine, University of Bern, Bern, Switzerland, ⁶University of Bern, Bern, Switzerland
Background/Purpose: Autoimmunity against citrullinated peptides is a hallmark of rheumatoid arthritis (RA). Chronic periodontitis (CP) is a known major source of citrullinated peptides. Here, we…
Abstract Number: 1097 • 2018 ACR/ARHP Annual Meeting
Spatial-Time Cluster Analysis of SLE Disease Activity
George Stojan¹, Anton Kvit², Frank Curriero² and Michelle Petri³, ¹Division of Rheumatology, Johns Hopkins University, Baltimore, MD, ²Bloomberg School of Public Health, Baltimore, MD, ³Johns Hopkins University School of Medicine, Baltimore, MD
Background/Purpose: Cluster detection is an essential tool in the public health domain with the goal of detecting anomalous clusters of disease cases. We performed a…
Abstract Number: 1607 • 2018 ACR/ARHP Annual Meeting
Achievement of Cdapsa Low Disease Activity or Remission Is Associated with Control of Articular and Extra-Articular Manifestations of Active Psa in Subjects Treated with Apremilast
Laura C. Coates¹, Philip J. Mease², Frank Behrens³, Ana-Maria Orbai⁴, Alexis Ogdie⁵, Michele Brunori⁶, Lichen Teng⁶, Benoit Guerette⁶ and Josef S. Smolen⁷, ¹University of Oxford, Oxford, United Kingdom, ²Swedish Medical Center and University of Washington School of Medicine, Seattle, WA, ³Division of Rheumatology, Goethe University and Fraunhofer IME-TMP, Frankfurt, Germany, ⁴Johns Hopkins University School of Medicine, Baltimore, MD, ⁵University of Pennsylvania, Philadelphia, PA, ⁶Celgene Corporation, Summit, NJ, ⁷Division of Rheumatology, Department of Internal Medicine III,, Medical University of Vienna and Hietzing Hospital, Vienna, Austria
Background/Purpose: Therapeutic targets for psoriatic arthritis (PsA) include the achievement of remission (REM) or low disease activity (LDA), measured by the Clinical Disease Activity Index…
Abstract Number: 1763 • 2018 ACR/ARHP Annual Meeting
Characterizing the Gut and Plasma Metabolomes in Patients with ANCA-Associated Vasculitis
Catherine E. Najem¹, Jung-Jin Lee², Ceylan Tanes², Cassidy Strange², Elliot Friedman², Antoine G. Sreih¹, Rennie L. Rhee¹, Abdallah Geara³, Hongzhe Li⁴, Kyle Bittinger², James D. Lewis⁵, Gary Wu⁵ and Peter A. Merkel⁴, ¹Rheumatology, Division of Rheumatology, University of Pennsylvania, Philadelphia, PA, ²Division of Gastroenterology, Hepatology, and Nutrition, Children's Hospital of Philadelphia, Philadelphia, PA, ³Division of Nephrology and Hypertension, University of Pennsylvania, Philadelphia, PA, ⁴Department of Biostatistics, Epidemiology, and Informatics, University of Pennsylvania, Philadelphia, PA, ⁵Division of Gastroenterology, University of Pennsylvania, Philadelphia, PA
Background/Purpose:To explore the mechanisms by which an altered gut microbiota might predispose to ANCA-associated vasculitis (AAV), a comprehensive metabolic profiling of fecal and plasma bile…
Abstract Number: 2431 • 2018 ACR/ARHP Annual Meeting
Birth Outcomes and Disease Activity during Pregnancy in a Prospective Cohort of Women with Psoriatic Arthritis and Ankylosing Spondylitis
Chelsey J F Smith¹, Arthur Kavanaugh² and Christina D Chambers³, ¹Rheumatology, University of California San Diego, La Jolla, CA, ²University of California, San Diego, School of Medicine, La Jolla, CA, ³University of California San Diego Department of Pediatrics, La Jolla, CA
Background/Purpose: The goal of this prospective cohort study is to add to the limited data on birth outcomes in psoriatic arthritis (PsA) and ankylosing spondylitis…
Abstract Number: 2625 • 2018 ACR/ARHP Annual Meeting
TNF Inhibitor Reduces ASDAS Faster and More Stable in Ankylosing Spondylitis Patients: Results from a Real World Prospective Cohort Managed By Smart Phone System
Xiaojian Ji, Jian Zhu, Jianglin Zhang and Feng Huang, Rheumatology, Chinese PLA General Hospital, Beijing, China
Background/Purpose: The Smart-phone Spondyloarthritis Management System (SpAMS) is a mobile health tool, specifically designed to conduct prospective clinical studies on SpA/AS in China, using real-world…
Abstract Number: 2949 • 2018 ACR/ARHP Annual Meeting
African American and European American SLE Patients with Variable Disease Activity Reveal Distinct Differences in B Cells and TLR7/8 Pathways
Samantha Slight-Webb¹, Miles C. Smith¹, Holden T. Maecker², Paul J. Utz³, Joel M. Guthridge¹ and Judith A. James⁴, ¹Arthritis and Clinical Immunology, Oklahoma Medical Research Foundation, Oklahoma City, OK, ²Stanford University, Stanford, CA, ³Medicine, Stanford University School of Medicine, Stanford, CA, ⁴Arthritis & Clinical Immunology, Oklahoma Medical Research Foundation, Oklahoma City, OK
Background/Purpose: Systemic lupus erythematosus (SLE) is an autoimmune disorder with a heterogeneous clinical presentation and periods of waxing and waning disease. Heterogeneity in SLE is…
Abstract Number: 321 • 2018 ACR/ARHP Annual Meeting
In Rheumatoid Arthritis All Disease Activities Are Not Created Equal
Keith Knapp¹ and Gary Craig², ¹Discus Analytics LLC, Spokane, WA, ²Discus Analytics LLC., Spokane, WA
Background/Purpose: Multiple composite RA disease activity (DA) metrics are approved for use; each reflect different aspects of disease. Many use similar measurements but their values…
Abstract Number: 589 • 2018 ACR/ARHP Annual Meeting
DAS28-CRP Versus DAS28-ESR and Thresholds for Disease Activity Category: Blinded Data from the Ongoing Phase IIb Trial with the EP4 Receptor Antagonist CR6086 in DMARD-Naïve Patients with Early Rheumatoid Arthritis
Cristina Vitalini, Beatrice Barbetta, Giampaolo Giacovelli, Nadia Brambilla, Massimo D'Amato, Federica Girolami and Lucio C. Rovati, Clinical Research Department, Rottapharm Biotech, Monza, Italy
Background/Purpose: In most patients with rheumatoid arthritis (RA) the 28-Joint Disease Activity Score (DAS28) values calculated using C-reactive protein (CRP) are lower than those calculated…
Abstract Number: 1192 • 2018 ACR/ARHP Annual Meeting
The Impact of Participation in an Adalimumab (Humira) Patient Support Program on the Onset and Management of Disease Flares
Filip van Den Bosch¹, Siegfried Wassenberg², Boulos Haraoui³, Patrick Zueger⁴, Meijing Wu⁴, Ivan Lagunes Galindo⁴ and Andrew Ostor⁵, ¹Ghent University Hospital, Ghent, Belgium, ²Rheumazentrum Ratingen, Ratingen, Germany, ³Université de Montréal, Montreal, QC, Canada, ⁴AbbVie Inc., North Chicago, IL, ⁵Cabrini Medical Center, Melbourne, Australia
Background/Purpose: The AbbVie patient (pt) support program (PSP) is offered to pts prescribed adalimumab for RA and other indications. The purpose of this analysis was…
Abstract Number: 1610 • 2018 ACR/ARHP Annual Meeting
Incremental Benefits to Quality of Life Associated with Achieving Higher Levels of American College of Rheumatology Response and Skin Clearance in Patients with Psoriatic Arthritis
Josef S. Smolen¹, David Shrom², Chen-Yen Lin², Julie Birt², Georg Schett³ and Alice B Gottlieb⁴, ¹Division of Rheumatology, Department of Medicine 3, Medical University of Vienna, Vienna, Austria, ²Eli Lilly and Company, Indianapolis, IN, ³Medical Clinic 3, Friedrich-Alexander University, Erlangen-Nuremberg, Germany, ⁴Department of Dermatology, New York Medical College, New York, NY
Background/Purpose: PsA is a chronic inflammatory disease associated with psoriasis. For optimal quality of life (QoL) improvements, all PsA symptoms should be managed. We examine…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].